Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-02 vs Rituximab in untreated CD20+ DLBCL
NCT04361279Phase 3Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab biosimilar SIBP-02 in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Institute of Biological Products. Started Jul 2019; status: completed.
02
Drugs
rituximab biosimilar SIBP-02
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04361279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361279.